Merck to spin old drugs into ‘NewCo’ focused on generics, women’s healthMerck & Co has followed the lead of other big pharma groups like Pfizer and GlaxoSmithKline by hiving Share XMerck to spin old drugs into ‘NewCo’ focused on generics, women’s healthhttps://pharmaphorum.com/news/merck-to-spin-old-drugs-into-newco-focused-on-generics-womens-health/
Celltrion plans to launch a biosimilar each year for next decadeThere are plenty of pharma companies outlining their strategies for the new decade this week at the JP Share XCelltrion plans to launch a biosimilar each year for next decadehttps://pharmaphorum.com/news/celltrion-plans-to-launch-a-biosimilar-each-year-for-next-decade/
Amgen, Allergan join Rituxan biosimilar challenge with FDA filingAmgen and Allergan have filed for approval of their biosimilar version of Roche’s CD20-targeting drug Rituxan with the Share XAmgen, Allergan join Rituxan biosimilar challenge with FDA filinghttps://pharmaphorum.com/news/amgen-allergan-join-rituxan-biosimilar-challenge-with-fda-filing/
FDA takes another step to encourage copycat insulin productsThe FDA has made another move to allow biosimilars get to market in the US more quickly, this Share XFDA takes another step to encourage copycat insulin productshttps://pharmaphorum.com/news/fda-takes-another-step-to-encourage-copycat-insulin-products/
First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bidChina’s Henlius Biotech has pressed go on a $477 million initial public offering (IPO) on the Hong Kong Share XHenlius Biotech shrugs off Hong Kong disruption with $477M IPO bidhttps://pharmaphorum.com/news/henlius-biotech-shrugs-off-hong-kong-disruption-with-477m-ipo-bid/
Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
Mylan’s Lantus biosimilar held up by manufacturing issueMylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient Share XMylan’s Lantus biosimilar held up by manufacturing issuehttps://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in EuropeTwo biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada Share XLilly faces biosimilar rivals to osteoporosis drug Forsteo in Europehttps://pharmaphorum.com/news/lilly-faces-biosimilar-rivals-to-osteoporosis-drug-forsteo-in-europe/
